Comparison of three different prophylactic treatments for postoperative nausea and vomiting after total joint arthroplasty under general anesthesia: a randomized clinical trial

Springer Science and Business Media LLC
Jinwei Xie1, Yingcun Cai1, Fuxing Pei1
1Department of Orthopaedic Surgery, West China Hospital, Sichuan University, 37#Guoxue Road, Chengdu, Sichuan Province, 610041, People’s Republic of China

Tóm tắt

Abstract Background Postoperative nausea and vomiting (PONV) after total joint arthroplasty is common and associated with delayed recovery. This study was performed to evaluate the efficacy of three different prophylactic regimens for PONV after total joint arthroplasty under general anesthesia. Methods Patients undergoing primary total hip or knee arthroplasty were randomized to Group A (ondansetron), Group B (10 mg dexamethasone plus ondansetron and mosapride), or Group C (three doses of 10 mg dexamethasone plus ondansetron and mosapride). The primary outcome was the total incidence of PONV during postoperative 48 h. The secondary outcomes were complete response, rescue antiemetic treatment, opioid consumption, time until first defecation, postoperative appetite score, satisfaction score, length of hospital stay, blood glucose level, and complications. Results Patients in Group C experienced a lower incidence of total PONV (29.3%, p = 0.001) and a higher incidence of complete response (70.7%, p = 0.001) than did patients in Group A (51.9%, 48.2%, respectively). Patients in Group C also experienced a lower incidence of severe PONV (4.3%) than patients in Group A (25.9%, p<0.001) and B (20.4%, p<0.001). Moreover, less rescue antiemetic treatment (1.4 ± 0.5 mg Metoclopramide) and postoperative opioid consumption (1.8 ± 0.3 mg Oxycodone, 6.0 ± 1.0 mg Pethidine) was needed in Group C. Additionally, a shorter time until first defecation, shorter length of stay, and better postoperative appetite scores and satisfaction scores were detected in patients in Group C. A slight increase in the fasting blood glucose level was observed in Group C, and the complications were comparable among the groups. Conclusion Combined use of ondansetron, mosapride and three doses of dexamethasone can provide better antiemetic effectiveness, postoperative appetite, bowel function recovery, and pain relief than a single dose or ondansetron only. Trial registration information The protocol was registered at the Chinese Clinical Trial Registry (ChiCTR1800015896, April 27, 2018).

Từ khóa


Tài liệu tham khảo

Lin CJ, Williams BA. Postoperative nausea and vomiting in ambulatory regional anesthesia. Int Anesthesiol Clin. 2011;49(4):134–43.

Sansonnens J, Taffe P, Burnand B. Group ADSs: higher occurrence of nausea and vomiting after total hip arthroplasty using general versus spinal anesthesia: an observational study. BMC Anesthesiol. 2016;16(1):44.

Sculco PK, Pagnano MW. Perioperative solutions for rapid recovery joint arthroplasty: get ahead and stay ahead. J Arthroplasty. 2015;30(4):518–20.

Nathan N. Management of postoperative nausea and vomiting: the 4th Consensus guidelines. Anesth Analg. 2020;131(2):410.

Benhamou D. Postoperative nausea and vomiting: is the big little problem becoming a smaller little problem? Br J Anaesth. 2023;131(1):22–5.

Ross-Adjie GM, Monterosso L, Bulsara M. Bowel management post major joint arthroplasty: results from a randomised controlled trial. Int J Orthop Trauma Nurs. 2015;19(2):92–101.

Xu B, Ma J, Huang Q, Huang ZY, Zhang SY, Pei FX. Two doses of low-dose perioperative dexamethasone improve the clinical outcome after total knee arthroplasty: a randomized controlled study. Knee Surg Sports Traumatol Arthrosc. 2018;26(5):1549–56.

Lei YT, Xu B, Xie XW, Xie JW, Huang Q, Pei FX. The efficacy and safety of two low-dose peri-operative dexamethasone on pain and recovery following total hip arthroplasty: a randomized controlled trial. Int Orthop. 2018;42(3):499–505.

Lei Y, Huang Q, Xu B, Zhang S, Cao G, Pei F. Multiple low-dose dexamethasone further improves clinical outcomes following total hip arthroplasty. J Arthroplasty. 2018;33(5):1426–31.

Vuorinen MA, Palanne RA, Makinen TJ, Leskinen JT, Huhtala H, Huotari KA. Infection safety of dexamethasone in total hip and total knee arthroplasty: a study of eighteen thousand, eight hundred and seventy two operations. Int Orthop. 2019;43(8):1787–92.

Cai YXJ, Ma J, Pei F. Risk factors of postoperative nausea and vomiting following primary total hip or knee arthroplasty under general anesthesia:a retrospective study. Chin J Bone Joint Surg. 2016;9(1):5.

Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396(10263):1664–74.

Ganesan P, Sharma A, Mohanti BK, Gogia A. Protracted cisplatin-induced vomiting responding to mosapride. Indian J Cancer. 2010;47(1):73–4.

Xie J, Cai Y, Ma J, Huang Q, Pei F. Oral mosapride can provide additional anti-emetic efficacy following total joint arthroplasty under general anesthesia: a randomized, double-blinded clinical trial. BMC Anesthesiol. 2020;20(1):297.

Reibaldi M, Fallico M, Longo A, Avitabile T, Astuto M, Murabito P, Minardi C, Bonfiglio V, Boscia F, Furino C et al. Efficacy of three different prophylactic treatments for postoperative nausea and vomiting after vitrectomy: a Randomized Clinical Trial. J Clin Med 2019, 8(3).

Ursavas FE, Baksi A, Sarica E. Postoperative nausea and vomiting after orthopaedic surgery: prevalence and Associated factors. Orthop Nurs. 2023;42(3):179–87.

Schlesinger T, Meybohm P, Kranke P. Postoperative nausea and vomiting: risk factors, prediction tools, and algorithms. Curr Opin Anaesthesiol. 2023;36(1):117–23.

Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350(24):2441–51.

Yoshida B, Piple AS, Wang JC, Richardson MK, Christ AB, Heckmann ND. Perioperative Dexamethasone Associated with decreased length of stay after total hip and knee arthroplasty. J Am Acad Orthop Surg. 2023;31(19):e778–87.

Xu H, Zhang S, Xie J, Lei Y, Cao G, Pei F. Multiple doses of Perioperative Dexamethasone further improve clinical outcomes after total knee arthroplasty: a prospective, randomized, controlled study. J Arthroplasty. 2018;33(11):3448–54.

Machekposhti A, Soltani S, Najafizadeh M, Ebrahimi P, Chen SA. Biocompatible polymer microneedle for topical/dermal delivery of tranexamic acid. J Control Release. 2017;261:87–92.

Lunn TH, Kehlet H. Perioperative glucocorticoids in hip and knee surgery - benefit vs. harm? A review of randomized clinical trials. Acta Anaesthesiol Scand. 2013;57(7):823–34.

Yue C, Wei R, Liu Y. Perioperative systemic steroid for rapid recovery in total knee and hip arthroplasty: a systematic review and meta-analysis of randomized trials. J Orthop Surg Res. 2017;12(1):100.

Koh IJ, Chang CB, Lee JH, Jeon YT, Kim TK. Preemptive low-dose dexamethasone reduces postoperative emesis and pain after TKA: a randomized controlled study. Clin Orthop Relat Res. 2013;471(9):3010–20.

Mine Y, Oku S, Yoshida N. Anti-emetic effect of mosapride citrate hydrate, a 5-HT4 receptor agonist, on selective serotonin reuptake inhibitors (SSRIs)-induced emesis in experimental animals. J Pharmacol Sci. 2013;121(1):58–66.

Bergeron R, Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry. 1994;151(7):1084–6.

Polderman JA, Farhang-Razi V, Van Dieren S, Kranke P, DeVries JH, Hollmann MW, Preckel B, Hermanides J. Adverse side effects of dexamethasone in surgical patients. Cochrane Database Syst Rev. 2018;11:CD011940.

Dissanayake R, Du HN, Robertson IK, Ogden K, Wiltshire K, Mulford JS. Does Dexamethasone Reduce Hospital readiness for Discharge, Pain, nausea, and early patient satisfaction in hip and knee arthroplasty? A Randomized, Controlled Trial. J Arthroplasty. 2018;33(11):3429–36.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả